P1735: IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN MITAPIVAT-TREATED PATIENTS WITH PYRUVATE KINASE DEFICIENCY: A DESCRIPTIVE ANALYSIS FROM THE PHASE 3 ACTIVATE TRIAL
K. H. Kuo,
R. F. Grace,
E. J. van Beers,
W. Barcellini,
A. Glenthøj,
S. Holzhauer,
P. Patel,
V. Beynon,
J. Li,
E. Zagadailov,
H. Al-Samkari
Affiliations
K. H. Kuo
1 Division of Hematology, University of Toronto, Toronto, Canada
R. F. Grace
2 Dana-Farber/Boston Children’s Cancer and Blood Disorder Center, Harvard Medical School, Boston, United States of America
E. J. van Beers
3 Van Creveldkliniek, Department of Internal Medicine, University Medical Center Utrecht, Netherlands
W. Barcellini
4 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
A. Glenthøj
5 Department of Hematology, Rigshospitalet, Copenhagen, Denmark
S. Holzhauer
6 Department of Pediatric Hematology and Oncology, Charité University Medicine, Berlin, Germany
P. Patel
7 Agios Pharmaceuticals, Inc., Cambridge
V. Beynon
7 Agios Pharmaceuticals, Inc., Cambridge
J. Li
7 Agios Pharmaceuticals, Inc., Cambridge
E. Zagadailov
7 Agios Pharmaceuticals, Inc., Cambridge
H. Al-Samkari
8 Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, United States of America
